好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Validation of a Multimodal EEG-based Index to Aid in Diagnosing and Tracking Concussion Among Athletes
Concussion Management
P1 - Poster Session 1 (7:00 AM-3:15 PM)
029

Objective: The goal of this study was to validate an EEG based multimodal index to aid in the assessment of concussion at time of injury, severity of concussion, and aid in evaluating readiness to return to play/activity.

Background:  The absence of a gold standard for diagnosis of concussion results in reliance on subjective self-report of symptoms. EEG has been demonstrated to be sensitive to changes in brain function following head injury, especially in connectivity. Using machine learning with inputs primarily from EEG measures, and including multimodal inputs, an objective marker of the likelihood of concussion (Concussion Index, CI) was derived. 

Methods:  Male and female concussed athletes and controls ages of 13-25yr, represented a convenience sample (n=580), enrolled from US High School, Colleges, and Concussion Clinics.  Concussed subjects had a witnessed head impact and were removed from play by site guidelines.  Assessments were performed within 72 hours of injury, at clinically determined return to play (RTP), 45 days following RTP, and included EEG (frontal and frontotemporal regions), neurocognitive performance, and standard concussion assessments.

Results:  Sensitivity = 85.99%, Specificity = 70.78%, NPV = 90.10% and PPV = 62.02, were obtained. Results demonstrated significance: 1) between CI at injury compared to RTP (p<0.0001); 2) between CI in patients with rapid (<14 days) compared with those with prolonged recovery (≥14 days), (p=0.0038); 3) stability over time in controls (p<0.0001); and 4) between CI and total symptom burden (correlation coefficient 0.8031, p<0.0001).

Conclusions: This study independently validated a multimodal, EEG-based, objective index of concussion (CI).  The neurotechnology platform incorporating this capability is handheld, rapid to use, and lends itself to incorporation into the standard assessment of concussion to aid in clinical diagnosis and assessment of readiness to RTP. This data supported the FDA clearance for the Concussion Index (embedded in the BrainScope medical device).

Authors/Disclosures
Jeffrey J. Bazarian, MD (University of Rochester Medical Center)
PRESENTER
Dr. Bazarian has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for abbott. Dr. Bazarian has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for BioMerieux. The institution of Dr. Bazarian has received research support from BrainBox Solutions. The institution of Dr. Bazarian has received research support from Abbott.
Leslie S. Prichep, PhD (Wave Neuroscience) Dr. Prichep has received personal compensation for serving as an employee of BrainScope Company. Dr. Prichep has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for WAVE Neuroscience. Dr. Prichep has received intellectual property interests from a discovery or technology relating to health care.